Quick Answer
Tvardi Therapeutics, Inc. reported Diluted EPS of $3.26 per share (loss) for fiscal year 2025.
Tvardi Therapeutics, Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$3.26 | +71.5% |
| 2024 | -$11.42 | +56.5% |
| 2023 | -$26.26 | -37.3% |
| 2022 | -$19.12 | -998.9% |
| 2021 | -$1.74 | -1066.7% |
| 2020 | $0.18 | +107.2% |
| 2019 | -$2.49 | -20.9% |
| 2018 | -$2.06 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$0.59 | +72.4% | +41.0% |
| June 30, 2025 | -$1.00 | +63.1% | +68.9% |
| March 31, 2025 | -$3.22 | +84.1% | -50.5% |
| September 30, 2024 | -$2.14 | -311.5% | +21.0% |
| June 30, 2024 | -$2.71 | -367.2% | +86.6% |
| March 31, 2024 | -$20.24 | -4030.6% | -3792.3% |
| September 30, 2023 | -$0.52 | -20.9% | +10.3% |
| June 30, 2023 | -$0.58 | -625.0% | -18.4% |
- Tvardi Therapeutics, Inc. showed an increase of +71.5% in Diluted EPS compared to the prior fiscal year.
- Over the 2018–2025 period, Tvardi Therapeutics, Inc.’s diluted eps has declined by 58.3% (from $2.06 per share (loss) to $3.26 per share (loss)).
- The most recent figure is from Tvardi Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 31, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: